Notably, NKG2A is the main regulator of NKA in PCa before and after prostatectomy, and the development of methods to prevent EV‐associated NKG2A inhibition may enhance the efficacy of immunotherapy in PCa patients. This evidence concerns the gene TAC1 and posterior cortical atrophy.